← Back to headlines
ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf.
ANI Pharmaceuticals outlined its strategic vision at the Raymond James Conference, aiming for over $1 billion in sales by 2026, with a key focus on expanding its presence in the rare disease market.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Corporate Dividend Declarations Include Nvidia, Mosaic, and Alamos Gold
29m ago
Build-A-Bear Slashes Revenue Forecast and Replaces Executive After Summer Sales Miss
30m ago
Major Canadian Banks Report Strong Third-Quarter Earnings, Beating Forecasts
56m ago
Anthropic Introduces Framework for AI Agents to Control Physical Devices
1h ago